Rationale: Induction of heme oxygenase-1 (HO-1) protects the liver against reperfusion injury after hemorrhagic shock (H/R). Previous data suggest, that the 1 -adrenoceptor-agonist dobutamine induces HO-1 in hepatocytes.
assess the organ specific expression of HO-1. Liver, heart, aorta, lung, kidney, and jejunum were harvested at the end of the experiment and stored at -70°C until further processing.
Sham-operated animals (n=8) received a constant infusion of 10 mL/kg/h Ringer's solution during the entire period of the experiment but did not undergo hemorrhage.
Preconditioning protocol: Animals received either 10 mL/kg/h Ringer's ("Vehicle/Shock"; n=9) or 10 µg/kg/min dobutamine ("Dob/Shock"; n=9) or a combination of 10 µg/kg/min dobutamine and 500 µg/kg/min of the ß 1 -adrenoceptorantagonist esmolol ("Dob/Esmolol/Shock"; n=5) for 6 h before induction of hemorrhagic shock. Drug infusion was stopped 30 minutes before the onset of hemorrhagic shock.
In control experiments the HO-pathway was blocked after dobutamine pretreatment with the false substrate tin mesoporphyrin-IX (SnMP-IX; Porphyrin Products, Logan) 15 min before induction of hemorrhagic shock ("Dob/SnMP/Shock"; n=9). SnMP-IX was prepared and administered as described previously (15) .
To assess the role of CO animals received 100 mg/kg of the CO-donor Dichloromethane (DCM) 6 hours before induction of shock ("DCM/Shock"; n=9).
DCM was administered via a stomach tube. CO blood content was measured spectrophotometrically at baseline and before induction of hemorrhagic shock.
Results:

Dose-dependent hepatocellular induction of HO-1 after dobutamine treatment
In dose-response experiments animals were treated with 10, 20 or 50 µg/kg/min dobutamine for 6 hours or received 10 mL/kg/h Ringer's solution (Sham). Untreated animals served as controls. HO-1 protein was barely detectable in livers from unmanipulated controls. A slight induction of HO-1 was observed in sham-operated animals, while a significant and dose-dependent increase of HO-1-immunoreactive protein after treatment with dobutamine was observed in vivo ( Fig. 1 ).
Immunohistochemical detection of HO-1 expression
Cell-type-specific and spatial expression pattern of HO-1 on the protein level was studied by immunohistochemistry. Representative liver sections were obtained from time-matched sham-operated controls, animals treated with 10 µg/kg/min dobutamine, or animals treated with 50 µg/kg/min dobutamine for 6 hours. 
Organ specific induction of HO-1 after dobutamine treatment
In control experiments animals were treated with 10 µg/kg/min dobutamine for 6 hours. Compared to sham operated controls a profound de novo synthesis of HO-1 immunoreactive protein was observed in liver, heart, aorta, lung, kidney, and jejunum after dobutamine treatment (Fig. 3) .
Macrohemodynamic parameters
Baseline values of MAP, heart rate, and cardiac output were comparable in all groups. Sham-operated animals exhibited normal and stable hemodynamic conditions throughout the experiment. Treatment with 10 µg/kg/min dobutamine led to a significant increase in heart rate ( Fig. 4 A) , while no significant differences in MAP were observed (Fig. 4 B) . Cardiac output was increased during preconditioning with dobutamine (Fig. 4 C) . A decrease in heart rate and cardiac output towards baseline was observed within 15 min after termination of dobutamine pretreatment. Dob/Esmolol/Shock-animals showed comparable hemodynamic parameters to the Vehicle/Shock-group. Before onset of hemorrhagic shock all groups exhibited comparable macrohemodynamic conditions. Induction of hemorrhagic shock led to a initial profound decrease in heart rate in Vehicle/Shock-animals while it decreased only slightly in the Dob/Shock group (Fig. 4 A) . Hemorrhagic shock was reversible in all animals as reflected by recovery of MAP, heart rate and cardiac output after retransfusion of shed blood. Shed blood volumes (mL/kg) were comparable in all groups subjected to hemorrhagic shock (Table 1) , suggesting a comparable insult.
During reperfusion macrohemodynamic parameters were stable in all groups (Fig. 4) .
Blockade of the HO-pathway with SnMP in dobutamine-treated animals (Dob/SnMP/Shock) had no significant influence on macrohemodynamic parameters like MAP, heart rate and cardiac output compared to dobutamine-treated animals without blockade (Data not shown). Administration of DCM (DCM/Shock) did not lead to significant changes in MAP, heart rate and cardiac output compared to the Vehicle/Shock-group (Data not shown).
Blood gas analysis
Blood gas analysis was performed immediately after blood sampling. Baseline values of respiratory parameters (pO 2 , pCO 2 ), acid-base metabolism (pH, BE) and hemoglobin content (Hb) were comparable in all groups. A significant reduction of BE was observed in all shock groups indicating a comparable severity of hemorrhagic shock (#: p<0.05 compared to baseline). BE recovered during resuscitation in all shock groups (Table 2) .
ICG-plasma disappearance rate
Hemorrhagic shock and resuscitation significantly impaired PDR ICG compared to sham-operated animals. Pretreatment with dobutamine before induction of hemorrhagic shock improved PDR ICG . A combined pretreatment with dobutamine and esmolol impaired PDR ICG after hemorrhagic shock compared to dobutamine alone.
Blockade of the HO-pathway with SnMP-IX after dobutamine treatment abolished the observed protection. Application of the CO donor dichloromethane (DCM) before shock led to a significant increase in COHb (from 3.5 ± 0.56 % to 15.1 ± 3.51 %; p<0.001) and improved PDR ICG . (Fig. 5) .
Samples of sham-operated, vehicle-treated and dobutamine-treated (10 µg/kg/min) animals and animals treated simultaneously with dobutamine (10 µg/kg/min) and esmolol (500 µg/kg/min) were analysed. Dobutamine treatment for 6 hours led to a significant increase of HO-1 expression compared to sham-operated animals.
Blockade of 1 -adrenoceptors with the 1 -adrenoceptor-antagonist esmolol prevented this increase (Fig. 6) .
Influence of DCM pretreatment on HO-1 induction
In further control experiments the influence of DCM pretreatment on HO-1 induction in the liver was investigated to assess possible effects of the reagent on Hb inhibiting oxygen delivery and enhancing hypoxic preconditioning. No significant induction of HO-1 was observed after DCM treatment making a hypoxic preconditioning through DCM pretreatment unlikely (figure 7).
Determination of serum enzyme levels as markers of injury
Hepatocellular injury was assessed by measurement of serum enzyme levels of alanine aminotransferase (ALAT) and glutamate dehydrogenase (GLDH).
Troponin T was measured as a marker of cardiac injury. Lipase serum enzyme levels
were assessed as a marker of pancreatic injury. Creatinine levels were used as a marker of renal injury. Hemorrhage and subsequent resuscitation led to a significant increase in ALAT and GLDH activity in Vehicle/Shock as well as in Dob/Shock animals. No significant differences were observed between both groups (Fig. 8) .
Pretreatment with dobutamine decreased serum enzyme levels of troponin T compared to vehicle indicating less cardiac injury after dobutamine pretreatment (Fig. 9 ). No significant changes were observed for creatinine or lipase serum enzyme levels.
Discussion
In the present study we investigated the functional significance of pretreatment with This upregulation of HO-1 after preconditioning contributes to an improved hepatic function and perfusion after hemorrhagic shock which might be in part mediated through the increased HO-dependent production of CO. Furthermore, induction of HO-1 is observed in several other organs like heart, aorta, lung, jejunum, and kidneys after 6 hours of dobutamine pretreatment. Looking at markers of injury a decrease of troponin serum enzyme levels after dobutamine pretreatment indicates a protective role for cardiac injury after shock.
The phenomenon that pre-exposure of the liver to transient sublethal stress increases the tolerance to reperfusion injury is known as hepatic preconditioning.
Organ preconditioning is an emerging means of protecting the body against The organ-specific expression of HO-1 after dobutamine pretreatment showed an induction in the liver, heart, aorta, lung, kidney, and jejunum compared to sham operated controls. Serum enzyme levels after hemorrhagic shock with or without dobutamine pretreatment including the serum enzyme levels of troponin T as a marker of cardiac injury, the enzyme levels of lipase as a marker of pancreatic injury, and the serum enzyme levels of creatinine as a marker of kidney function showed unchanged creatinine and lipase levels, while troponin T was lower after dobutamine pretreatment. These data indicate a protective role of dobutamine pretreatment for cardiac injury after shock apart from the protective effects observed on liver function.
Different pathways of HO-1 induction under stress conditions have been described. In summary, our results indicate a 1 -adrenoceptor dependent induction of HO-1 resulting in a protection of hepatic function and perfusion during hemorrhagic shock.
In line with these results dobutamine pretreatment might be a potential means to Densitometric units are given as mean ± SD; * p<0,05 compared to control 
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Dobutamine pretreatment led to a significant increase in heart rate and cardiac output, while no significant changes in mean arterial pressure were observed.
Vehicle-treated animals and Dob/Esmolol/Shock-animals exhibited stable hemodynamic parameters during preconditioning. After termination of dobutamine administration heart rate and cardiac output in the Dob/Shock-group returned to baseline. At the onset of hemorrhagic shock all groups had comparable hemodynamics.
Induction of hemorrhagic shock led to a significant decrease in MAP and cardiac output in all groups. A significant decrease in heart rate was observed in Vehicle/Shock-animals, while it remained stable in dobutamine-pretreated animals.
After retransfusion of shed blood heart rate, MAP and cardiac output returned to baseline values in all groups. No significant differences in MAP between the groups were observed during the entire experiment. Pretreatment with Dobutamine did not increase plasma levels of ALAT or GLDH.
Hemorrhagic shock and reperfusion led to a significant increase in GLDH-and ALATactivity. No significant differences between vehicle-and dobutamine-treated animals were observed. Data are shown as mean ± SD. $ p<0.05 compared to baseline. $ p<0.05 compared to baseline, # p<0.05 compared to vehicle. Table 1 Shed blood volume No significant differences in shed blood volumes were observed to achieve a mean arterial blood pressure of 35 ± 5 mmHg in the shock groups. Data are means ± SD.
Power of the performed test 0,8. Table 2 Blood gas analysis
Baseline
End of preconditioning
End of shock
End of experiment
Blood gas analysis revealed normal baseline values of pO 2 [mmHg], pCO 2 
